Semaglutide was approved in 2022 for use alongside lifestyle changes in pediatric patients aged 12 or older with an initial BMI equal to or greater than the 95th percentile for their age and sex
Insurance typically only covers brand-name semaglutide (Ozempic, Wegovy)
EG is a paid consultant for Novartis, Flare Therapeutics, Reactive Biosciences and Seagen
It has been widely studied for its ability to lower blood sugar and improve metabolic health by enhancing GLP-1 secretion and insulin sensitivity
Additionally, both ENT1 and ENT2 are involved in the transport of antiviral nucleoside analog drugs, such as didanosine, zalcitabine, and zidovudine, as well as certain anticancer drugs like cytarabine and gemcitabine [95,96,97]